Precise individualized treatment-DIAGREAT therapeutic drug monitoring (TDM) chemiluminescence solution

Precise individualized treatment-DIAGREAT therapeutic drug monitoring (TDM) chemiluminescence solution


Precise individualized treatment-DIAGREAT therapeutic drug monitoring (TDM) chemiluminescence soluti

Traditional drug therapy model follows the group treatment of drugs, ignore individual differences in drug disposition and effect, and fail to achieve precise individualized treatment.


Clinicians judge and select corresponding therapeutic drugs based on clinical diagnosis, auxiliary examination results and their own clinical experience. This model ignores individual differences in drug disposition and effect, and cannot maximize the efficacy of drugs, avoid drug toxicity and side effects, and guide precise medication of patients.


Precise individualized treatment-DIAGREAT therapeutic drug monitoring (TDM) chemiluminescence soluti



For example

Children with hematological diseases are prone to invasive fungal infections due to invasive operations such as repeated chemotherapy, use of immunosuppressants and broad-spectrum antibacterial drugs, intravenous catheterization, and hematopoietic stem cell transplantation, and voriconazole is currently the drug of choice for the treatment of aspergillus infections in children.

Studies have found that voriconazole metabolic clearance in children is faster than that in adults, but its bioavailability is lower. If children follow the adult's dosage regimen, the drug exposure in the body will be too low, which will reduce the curative effect and increase the risk of treatment failure. Domestic and foreign research reports the incidence of adverse reactions in children treated with voriconazole was 3.0%-32.7%, mainly hepatotoxicity, followed by photosensitivity and rash. Therefore, monitoring the plasma concentration of voriconazole is helpful to guide individualized medication in children with hematological diseases.

Individualized Drug Therapy 

Precise individualized treatment-DIAGREAT therapeutic drug monitoring (TDM) chemiluminescence soluti

Individualized medication is to formulate safe, effective, reasonable and economical drug therapy regimen on the basis of fully considering the individual characteristics of each patient, such as genetic factors, gender, age, body weight, physiological and pathological characteristics, and combined medications, that is, 'give the most suitable drug and the most suitable dose to the most suitable patient at the most suitable time', and adjust the drug therapy regimen accordingly, which can significantly reduce blindness and irrational drug use and the occurrence of adverse drug reactions.



Opportunities and challenges in the international market



From the perspective of regional market distribution, the global in vitro diagnostic demand market is mainly distributed in developed economies such as North America, Europe, and Japan, of which North America accounts for more than 40% of the market share, Western Europe accounts for 20%, and Japan accounts for 9%. Together, it accounts for more than 70% of the global in vitro diagnostics market. In developed countries, due to the relatively complete medical services, the in vitro diagnostic market has entered a relatively stable mature stage, showing a trend of slowing down and steady development. Emerging markets represented by China, India, Latin America, etc., although the current market share is relatively small, due to the large population base, rapid economic growth, and the increasing degree of aging, in recent years, medical insurance investment and per capita medical consumption spending continues to grow and is in a period of rapid growth. Emerging markets are becoming the fastest growing regions in the global in vitro diagnostics market.


POCT is the world's largest segment of in vitro diagnostics, accounting for 29% in 2019, followed by microbial diagnosis with a market share of 21%. POCT and microbial diagnostics combined accounted for 50%, half of the market share. Biochemical diagnosis, immunodiagnosis, and molecular diagnosis are also the main application fields of in vitro diagnostics at present, accounting for more than 40% of the in vitro diagnostic market share in the global market.

DIAGREAT Fully Automated Chemiluminescence Therapeutic Drug Monitoring (TDM) Solution


DIAGREAT effectively provides comprehensive and perfect professional testing services for individualized rational drug use and precise diagnosis and treatment, to protect the safety of patients' medication!


DIAGREAT fully automated chemiluminescence therapeutic drug monitoring solution, with a test speed of up to 200T/H, has high-throughput, large-sample, and fully-automated detection performance, and truly achieves sample input and result output, unattended, and full-process quality control, with stable and reliable results. At the same time, DIAGREAT has achieved complete self-development and production of reagent raw materials, and has the ability to continuously launch new testing items. Currently, 15 drugs can be tested.



DIAGREAT Fully Automated Chemiluminescence Therapeutic Drug Monitoring (TDM) Solution



Testing speed up to 200 test/hour, the first result time 15 min


High capacity

25 reagent locations, 60 samples locations.


Small size

175kg, 100(length)*67(depth)*64(height)cm


Easy operation

batch testing mode, random testing mode, emergency mode


Therapeutic Drug Monitoring (TDM) items


Antiepileptic drugs

Anticancer drug


Cardiac Glycoside


Anti-tuberculosis drug

Antifungal drug


Routine testing items

Diabetes marker

Tumor marker


Cardiac marker

Thyroid function marker

Sexual hormone marker

Immune function marker

Coagulation marker

Inflammation/infection marker


Contact: 186-0018-8519



1. Research progress of personalized medicine based on the pharmacogenomics and blood drug concentration monitoring_Ni Weijian

2. Clinical Application of Therapeutic Drug Monitoring of Voriconazole in Children with Hematological Disease_Huang Zhizhuo


Related Recommendations